The National Cancer Institute approved the following clinical research studies last month.
For further information, contact the principal investigator listed.
Phase I – 10363
A Phase I Study of Pomalidomide and Nivolumab in Patients with Virus-Associated Malignancies with or Without HIV
NCI Center for Cancer Research
Lurain, Kathryn
(301) 250-5156
Phase I/II – 10417
Clinical Evaluation of ASTX727 in Combination with Venetoclax All-Oral Therapy vs Standard of Care Cytarabine and Anthracycline Induction Chemotherapy for Younger FLT3WT Patients with ELN High- Risk Acute Myeloid Leukemia
Yale University Cancer Center LAO
Savona, Michael Robert
(615) 936-3321
Phase I/II – 10428
A Phase I/II Study of Abemaciclib in Patients with HIV-Associated and HIV-Negative Kaposi Sarcoma
NCI Center for Cancer Research
Ramaswami, Ramya
(301) 451-9018
Phase II – NRG-BN010
A Safety Run-In and Phase II Study Evaluating the Efficacy, Safety, and Impact on the Tumor Microenvironment of the Combination of Tocilizumab, Atezolizumab, and Fractionated Stereotactic Radiotherapy in Recurrent Glioblastoma
NRG Oncology
Bagley, Stephen Joseph
(215) 614-1858
Phase III – URCC-19178
Optimizing Functional Outcomes of Older Cancer Survivors After Chemotherapy
University of Rochester NCORP Research Base
Mohile, Supriya Gupta
(585) 275-9319
Phase Pilot – AMC-111
Impact of Behavior Modification Interventions and Lung Cancer Screening on Smoking Cessation in People Living with HIV: A Feasibility Study
AIDS Malignancy Consortium
Sigel, Keith Magnus
(212) 824-7558
